Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Pancreatic Neoplasms 677Carcinoma, Non-Small-Cell Lung 324Neoplasms 168Breast Neoplasms 163Urinary Bladder Neoplasms 157Lung Neoplasms 157Neoplasm Metastasis 139Cholangiocarcinoma 111Ovarian Neoplasms 106Biliary Tract Neoplasms 91Lymphoma, Large B-Cell, Diffuse 73Nasopharyngeal Carcinoma 70Lymphoma 66Sarcoma 63Recurrence 62Gallbladder Neoplasms 60Carcinoma, Transitional Cell 55Triple Negative Breast Neoplasms 54Hodgkin Disease 52Colorectal Neoplasms 49Fallopian Tube Neoplasms 48Lymphoma, Non-Hodgkin 47Adenocarcinoma 45Bile Duct Neoplasms 40Carcinoma, Ovarian Epithelial 31Non-Muscle Invasive Bladder Neoplasms 30Uterine Cervical Neoplasms 28Carcinoma 28Unspecified Adult Solid Tumor, Protocol Specific 27Adenocarcinoma of Lung 27

Interventions

Paclitaxel 3Carboplatin 3tremelimumab 1pembrolizumab 1necitumumab 1envafolimab 1durvalumab 1anlotinib 1Nivolumab 1Gemcitabine 1Endostatins 1Drug Therapy 1Cisplatin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Squamous Non-small Cell Lung Cancer × Gemcitabine × Clear all
NCT01763788 2019-10-25

A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)

Eli Lilly and Company

Phase 1/2 Completed
192 enrolled 24 charts
Thoracic

Squamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡